NCT04771013View on ClinicalTrials.gov

Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

May 14, 2021

Study Completion Date

May 14, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Thymic peptides

250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.

Trial Locations (1)

22101

Hospital de Santa Bárbara Integrado, Santa Bárbara

All Listed Sponsors
collaborator

Pontificia Universidad Catolica de Chile

OTHER

lead

Universidad Católica de Honduras

OTHER

NCT04771013 - Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras | Biotech Hunter | Biotech Hunter